A citation-based method for searching scientific literature

Ana M Gonzalez-Angulo, Kirsten M Timms, Shuying Liu, Huiqin Chen, Jennifer K Litton, Jennifer Potter, Jerry S Lanchbury, Katherine Stemke-Hale, Bryan T Hennessy, Banu K Arun, Gabriel N Hortobagyi, Kim-Anh Do, Gordon B Mills, Funda Meric-Bernstam. Clin Cancer Res 2011
Times Cited: 358







List of co-cited articles
961 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
39

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
734
36


Triple-negative breast cancer: clinical features and patterns of recurrence.
Rebecca Dent, Maureen Trudeau, Kathleen I Pritchard, Wedad M Hanna, Harriet K Kahn, Carol A Sawka, Lavina A Lickley, Ellen Rawlinson, Ping Sun, Steven A Narod. Clin Cancer Res 2007
25

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright,[...]. N Engl J Med 2018
25

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, Xi Chen, Melinda E Sanders, A Bapsi Chakravarthy, Yu Shyr, Jennifer A Pietenpol. J Clin Invest 2011
24

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
Fergus J Couch, Steven N Hart, Priyanka Sharma, Amanda Ewart Toland, Xianshu Wang, Penelope Miron, Janet E Olson, Andrew K Godwin, V Shane Pankratz, Curtis Olswold,[...]. J Clin Oncol 2015
389
20

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Andrew Tutt, Holly Tovey, Maggie Chon U Cheang, Sarah Kernaghan, Lucy Kilburn, Patrycja Gazinska, Julie Owen, Jacinta Abraham, Sophie Barrett, Peter Barrett-Lee,[...]. Nat Med 2018
376
18

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M Sikov, Hope S Rugo, Mark D McKee, Jens Huober, Mehra Golshan, Gunter von Minckwitz, David Maag,[...]. Lancet Oncol 2018
297
18

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
994
17

Triple-negative breast cancer.
William D Foulkes, Ian E Smith, Jorge S Reis-Filho. N Engl J Med 2010
17

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
16

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
Steven J Isakoff, Erica L Mayer, Lei He, Tiffany A Traina, Lisa A Carey, Karen J Krag, Hope S Rugo, Minetta C Liu, Vered Stearns, Steven E Come,[...]. J Clin Oncol 2015
246
16

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
16

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
Gunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens U Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber,[...]. Lancet Oncol 2014
526
16

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
Matthew D Burstein, Anna Tsimelzon, Graham M Poage, Kyle R Covington, Alejandro Contreras, Suzanne A W Fuqua, Michelle I Savage, C Kent Osborne, Susan G Hilsenbeck, Jenny C Chang,[...]. Clin Cancer Res 2015
598
15

Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
Zora Baretta, Simone Mocellin, Elena Goldin, Olufunmilayo I Olopade, Dezheng Huo. Medicine (Baltimore) 2016
79
17

Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter Schmid, Javier Cortes, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck,[...]. N Engl J Med 2020
508
14

Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.
Anne-Renee Hartman, Rajesh R Kaldate, Lisa M Sailer, Lisa Painter, Charles E Grier, Robbin R Endsley, Marlena Griffin, Stephanie A Hamilton, Cynthia A Frye, Mark A Silberman,[...]. Cancer 2012
126
13

Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
Ellen R Copson, Tom C Maishman, Will J Tapper, Ramsey I Cutress, Stephanie Greville-Heygate, Douglas G Altman, Bryony Eccles, Sue Gerty, Lorraine T Durcan, Louise Jones,[...]. Lancet Oncol 2018
158
13


Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2008
12

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.
S R Young, Robert T Pilarski, Talia Donenberg, Charles Shapiro, Lyn S Hammond, Judith Miller, Karen A Brooks, Stephanie Cohen, Beverly Tenenholz, Damini Desai,[...]. BMC Cancer 2009
171
11

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Brian D Lehmann, Bojana Jovanović, Xi Chen, Monica V Estrada, Kimberly N Johnson, Yu Shyr, Harold L Moses, Melinda E Sanders, Jennifer A Pietenpol. PLoS One 2016
531
11

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
S Loibl, K E Weber, K M Timms, E P Elkin, E Hahnen, P A Fasching, B Lederer, C Denkert, A Schneeweiss, S Braun,[...]. Ann Oncol 2018
114
11

Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
Priyanka Sharma, Jennifer R Klemp, Bruce F Kimler, Jonathan D Mahnken, Larry J Geier, Qamar J Khan, Manana Elia, Carol S Connor, Marilee K McGinness, Joshua M W Mammen,[...]. Breast Cancer Res Treat 2014
98
10

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Deann P Atchley, Constance T Albarracin, Adriana Lopez, Vicente Valero, Christopher I Amos, Ana Maria Gonzalez-Angulo, Gabriel N Hortobagyi, Banu K Arun. J Clin Oncol 2008
363
10

Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.
Nancy U Lin, Ann Vanderplas, Melissa E Hughes, Richard L Theriault, Stephen B Edge, Yu-Ning Wong, Douglas W Blayney, Joyce C Niland, Eric P Winer, Jane C Weeks. Cancer 2012
320
10

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, R Tibshirani, T Aas, S Geisler, H Johnsen, T Hastie, M B Eisen, M van de Rijn, S S Jeffrey,[...]. Proc Natl Acad Sci U S A 2001
10

Gene-panel sequencing and the prediction of breast-cancer risk.
Douglas F Easton, Paul D P Pharoah, Antonis C Antoniou, Marc Tischkowitz, Sean V Tavtigian, Katherine L Nathanson, Peter Devilee, Alfons Meindl, Fergus J Couch, Melissa Southey,[...]. N Engl J Med 2015
529
10

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
10

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014
10

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
10

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Nasim Mavaddat, Daniel Barrowdale, Irene L Andrulis, Susan M Domchek, Diana Eccles, Heli Nevanlinna, Susan J Ramus, Amanda Spurdle, Mark Robson, Mark Sherman,[...]. Cancer Epidemiol Biomarkers Prev 2012
352
10

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani, Young-Hyuck Im, Eun-Sook Lee, Isao Yokota, Katsumasa Kuroi, Seock-Ah Im, Byeong-Woo Park, Sung-Bae Kim,[...]. N Engl J Med 2017
590
10

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Peter Schmid, Hope S Rugo, Sylvia Adams, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Volkmar Henschel, Luciana Molinero, Stephen Y Chui,[...]. Lancet Oncol 2020
374
10

BRCAness revisited.
Christopher J Lord, Alan Ashworth. Nat Rev Cancer 2016
638
9

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
Ayca Gucalp, Sara Tolaney, Steven J Isakoff, James N Ingle, Minetta C Liu, Lisa A Carey, Kimberly Blackwell, Hope Rugo, Lisle Nabell, Andres Forero,[...]. Clin Cancer Res 2013
395
9

Breast-cancer risk in families with mutations in PALB2.
Antonis C Antoniou, Silvia Casadei, Tuomas Heikkinen, Daniel Barrowdale, Katri Pylkäs, Jonathan Roberts, Andrew Lee, Deepak Subramanian, Kim De Leeneer, Florentia Fostira,[...]. N Engl J Med 2014
503
9

Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
Nadine Tung, Nancy U Lin, John Kidd, Brian A Allen, Nanda Singh, Richard J Wenstrup, Anne-Renee Hartman, Eric P Winer, Judy E Garber. J Clin Oncol 2016
277
9

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Carsten Denkert, Gunter von Minckwitz, Silvia Darb-Esfahani, Bianca Lederer, Barbara I Heppner, Karsten E Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto,[...]. Lancet Oncol 2018
681
9

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
Rita Nanda, Laura Q M Chow, E Claire Dees, Raanan Berger, Shilpa Gupta, Ravit Geva, Lajos Pusztai, Kumudu Pathiraja, Gursel Aktan, Jonathan D Cheng,[...]. J Clin Oncol 2016
832
9

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
S Adams, P Schmid, H S Rugo, E P Winer, D Loirat, A Awada, D W Cescon, H Iwata, M Campone, R Nanda,[...]. Ann Oncol 2019
294
9

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler,[...]. Lancet 2010
9

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D Ford, D F Easton, M Stratton, S Narod, D Goldgar, P Devilee, D T Bishop, B Weber, G Lenoir, J Chang-Claude,[...]. Am J Hum Genet 1998
9

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
William M Sikov, Donald A Berry, Charles M Perou, Baljit Singh, Constance T Cirrincione, Sara M Tolaney, Charles S Kuzma, Timothy J Pluard, George Somlo, Elisa R Port,[...]. J Clin Oncol 2015
517
9

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Aditya Bardia, Ingrid A Mayer, Linda T Vahdat, Sara M Tolaney, Steven J Isakoff, Jennifer R Diamond, Joyce O'Shaughnessy, Rebecca L Moroose, Alessandro D Santin, Vandana G Abramson,[...]. N Engl J Med 2019
275
9

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Melinda L Telli, Kirsten M Timms, Julia Reid, Bryan Hennessy, Gordon B Mills, Kristin C Jensen, Zoltan Szallasi, William T Barry, Eric P Winer, Nadine M Tung,[...]. Clin Cancer Res 2016
413
8

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Giampaolo Bianchini, Justin M Balko, Ingrid A Mayer, Melinda E Sanders, Luca Gianni. Nat Rev Clin Oncol 2016
8

A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
Saundra S Buys, John F Sandbach, Amanda Gammon, Gayle Patel, John Kidd, Krystal L Brown, Lavania Sharma, Jennifer Saam, Johnathan Lancaster, Mary B Daly. Cancer 2017
201
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.